Literature DB >> 3199810

Novel antioestrogens without partial agonist activity.

A E Wakeling1, J Bowler.   

Abstract

The oestrogenic and antioestrogenic properties of some novel 7 alpha-alkyl amide derivatives of 17 beta-oestradiol have been measured in rats and mice. The compound ICI 164384 was devoid of oestrogenic activity in the uterus and vagina of both species and on the hypothalamic-pituitary axis of the rat. ICI 164384 blocked completely the uterotrophic action of exogenous and endogenous oestradiol and of the partial agonist antioestrogens typified by tamoxifen. Unlike tamoxifen ICI 164384 did not promote premature vaginal opening in neonatal rats. The affinity of ICI 164384 for the rat uterus oestrogen receptor was substantially greater than that of tamoxifen. In MCF-7 and ZR-75-1 breast cancer cells in tissue culture ICI 164384 was a more potent inhibitor of cell growth than tamoxifen and growth inhibition was reversed by oestradiol. The properties of ICI 164384 satisfy many of the criteria which define pure antioestrogens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3199810     DOI: 10.1016/0022-4731(88)90014-3

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  25 in total

1.  IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.

Authors:  Yanxia Ning; Rebecca B Riggins; Jennifer E Mulla; Haniee Chung; Alan Zwart; Robert Clarke
Journal:  Mol Cancer Ther       Date:  2010-05       Impact factor: 6.261

2.  Gender-related differences in proliferative response of cardiac fibroblasts to hypoxia: effects of estrogen.

Authors:  M Griffin; H W Lee; L Zhao; M Eghbali-Webb
Journal:  Mol Cell Biochem       Date:  2000-12       Impact factor: 3.396

3.  The analysis of chimeric human/rainbow trout estrogen receptors reveals amino acid residues outside of P- and D-boxes important for the transactivation function.

Authors:  F G Petit; Y Valotaire; F Pakdel
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

4.  Comparative effect of embryonic mouse fibroblasts (Balb/c-3T3) on the proliferation of hormone-dependent (T-47D) and hormone-independent (MDA-MB-231) human breast cancer cell lines.

Authors:  G Chetrite; L Delalonde; J R Pasqualini
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.

Authors:  R A McClelland; D L Manning; J M Gee; E Anderson; R Clarke; A Howell; M Dowsett; J F Robertson; R W Blamey; A E Wakeling; R I Nicholson
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone.

Authors:  C L Smith; O M Conneely; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

7.  The influence of a novel cyclopropyl antiestrogen (compound 7a) on human breast cancer cells in culture.

Authors:  P T Jain; J T Pento; R A Magarian
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  17beta-Estradiol utilizes the estrogen receptor to regulate CD16 expression in monocytes.

Authors:  P R Kramer; V Winger; S F Kramer
Journal:  Mol Cell Endocrinol       Date:  2007-09-04       Impact factor: 4.102

9.  Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells.

Authors:  J C Reese; B S Katzenellenbogen
Journal:  Nucleic Acids Res       Date:  1991-12-11       Impact factor: 16.971

Review 10.  Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

Authors:  C K Osborne; A Wakeling; R I Nicholson
Journal:  Br J Cancer       Date:  2004-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.